Ozempic was originally approved by the FDA in 2017 as a treatment for type 2 diabetes. It was designed to help adults lower their blood sugar levels alongside diet and exercise, not to help people lose weight. The weight loss that made Ozempic a household name was actually a side effect noticed during diabetes clinical trials, and it took years before a higher-dose version of the same drug was separately approved for that purpose.
A Diabetes Drug First
Ozempic’s active ingredient, semaglutide, was developed by Novo Nordisk to improve blood sugar control in adults with type 2 diabetes. The drug is a synthetic version of a hormone your body naturally produces called GLP-1 (glucagon-like peptide-1), and the lab-made version shares about 94% of its structure with the natural hormone. When you eat, your gut releases GLP-1 to signal your pancreas to produce insulin. In people with type 2 diabetes, that system doesn’t work well enough on its own.
Semaglutide steps in by mimicking that hormone more persistently. It triggers insulin release when blood sugar is high and simultaneously suppresses glucagon, a hormone that raises blood sugar. It also helps protect the insulin-producing cells in the pancreas from dying off, which is one of the ways type 2 diabetes progressively worsens over time. The result is significantly better blood sugar control with just one injection per week, which was a meaningful improvement over older diabetes medications that required daily dosing.
How Well It Worked for Diabetes
Ozempic was tested in a series of clinical trials called SUSTAIN, which enrolled thousands of people with type 2 diabetes across multiple countries. The results were striking. In the SUSTAIN FORTE trial, patients taking the higher 2 mg dose saw their A1C levels drop by an average of 2.2 percentage points over 40 weeks. Even the lower 1 mg dose reduced A1C by 1.9 percentage points. For context, an A1C reduction of even 1 percentage point is considered clinically meaningful, so these were substantial improvements that put Ozempic among the most effective diabetes medications available.
A1C is a measure of average blood sugar over the previous two to three months, and keeping it under control is the central goal of diabetes management. Uncontrolled blood sugar damages blood vessels and nerves over time, leading to complications like kidney disease, vision loss, and nerve pain in the hands and feet. The size of the A1C reductions in the SUSTAIN trials positioned Ozempic as a top-tier option for people whose diabetes wasn’t adequately controlled by other medications.
Weight Loss Was a Side Effect
During those same diabetes trials, researchers consistently noticed that patients on semaglutide were losing weight, sometimes a lot of it. This wasn’t the primary goal of the studies, but the numbers kept showing up. Across the SUSTAIN trials, patients lost an average of roughly 5 to 7 kilograms (about 11 to 15 pounds) depending on the dose and the specific trial. In one study, patients on semaglutide lost an average of 5.8 kg compared to just 1.9 kg in the comparison group.
This makes biological sense. GLP-1 doesn’t just act on the pancreas. It also works in the brain, where it reduces appetite and slows the rate at which your stomach empties after a meal. People taking Ozempic often describe feeling full sooner and thinking about food less. These effects were always present in the drug’s mechanism, but diabetes researchers initially treated them as a welcome bonus rather than the main event.
Those weight loss signals prompted Novo Nordisk to test semaglutide at higher doses specifically for weight management. That led to a separate product called Wegovy, which the FDA approved for chronic weight management in 2021. Wegovy uses the same molecule as Ozempic but at a higher maximum dose: 2.4 mg per week compared to Ozempic’s maximum of 2 mg. The distinction matters because Ozempic is still officially a diabetes drug, even though it became widely prescribed off-label for weight loss.
The Cardiovascular Surprise
The story didn’t stop at blood sugar and weight. In March 2024, the FDA approved semaglutide (under the Wegovy brand) to reduce the risk of heart attack, stroke, and cardiovascular death in adults with heart disease who also have obesity or are overweight. This was based on a major trial of more than 17,600 participants that found serious cardiovascular events occurred in 6.5% of people taking semaglutide compared to 8% of those on placebo. That 1.5 percentage point difference translates to roughly a 20% relative reduction in risk.
This was a landmark moment. It marked the first time the FDA approved any treatment specifically to reduce heart risk in people with obesity or overweight. The cardiovascular benefits appear to come from a combination of factors: lower inflammation, improved blood vessel function, weight loss, and better metabolic health overall. For a drug that started as a blood sugar medication, this was a significant expansion of its medical identity.
Why the Original Purpose Still Matters
The explosion of interest in Ozempic for weight loss has sometimes overshadowed the people who need it most: those with type 2 diabetes. Shortages driven by off-label demand have at times made it harder for diabetes patients to get their prescriptions filled. Understanding that Ozempic was built from the ground up as a diabetes treatment helps explain why endocrinologists and diabetes specialists have been vocal about protecting access for their patients.
It also helps explain some of the confusion around dosing. People using Ozempic off-label for weight loss are taking a drug at doses optimized for blood sugar control, not weight management. Wegovy’s higher maximum dose reflects the clinical data showing that more semaglutide produces more weight loss. The two products contain identical molecules but serve different populations at different doses, a distinction that traces directly back to Ozempic’s origins as a diabetes-first medication.